Physician

Hematology

Dr. Ann T. Farrell, MD

Farrell is an expert in the field of Hematology. She attended Rush Medical College. Dr. Ann T. Farrell is a published physician. She has 23 papers published. The most current publication "FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia."

Publications

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
FDA approval: siltuximab for the treatment of patients with multicentric castleman disease.
FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma.
Gemtuzumab ozogamicin.
U.s. Food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed hodgkin lymphoma or relapsed systemic anaplastic large-cell lymph...
U.s. Food and drug administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Expediting the availability of drugs for US patients with cancer.
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
FDG-PET lymphoma demonstration project invitational workshop.
Sorafenib for the treatment of advanced renal cell carcinoma.
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Development of effective new treatments for multiple myeloma.
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
Oncology drug review process.
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.
The advisory process for anticancer drug regulation: a global perspective.
A strategic framework for novel drug development in multiple myeloma.

Schools

Rush University

Doctors Specialties

Hematology
Medical Oncology
Oncology

Accepted Insurances

Education

University of Massachusetts
Yale-New Haven Hospital
Rush Medical College

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Aron Primack, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Michael C. Goodman, MD
	Dr. Virginia E. Maher, MD
	Dr. Chin-Yung Chang, MD
	Dr. Clara S. Chan, MD This Doctor is OpenDoctor Recommended.
	Dr. William K. Kelly, MD This Doctor is OpenDoctor Recommended.
	Dr. Patrick A. Cross, MD This Doctor is OpenDoctor Recommended.
	Dr. Peter B. Sherer, MD This Doctor is OpenDoctor Recommended.
	Dr. Alida M. Espinoza, MD This Doctor is OpenDoctor Recommended.
	Dr. Frederick D. Min, MD This Doctor is OpenDoctor Recommended.
	Dr. Gurdeep Chhabra, MD This Doctor is OpenDoctor Recommended.
	Dr. Kashif Firozvi, MD This Doctor is OpenDoctor Recommended.
	Dr. Linda M. Burrell, MD This Doctor is OpenDoctor Recommended.
	Dr. Kashif Ali, MD
	Dr. Qin C. Ryan, MD
	Dr. Gwynn C. Ison, MD